Equities

Regenxbio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Regenxbio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.99
  • Today's Change-0.36 / -4.31%
  • Shares traded30.00
  • 1 Year change+9.15%
  • Beta1.1100
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Regenxbio Inc has grown net income from a loss of -263.49m to a smaller loss of -227.10m despite declining revenues.
Gross margin87.18%
Net profit margin-110.29%
Operating margin-96.04%
Return on assets-34.07%
Return on equity-76.88%
Return on investment-43.55%
More ▼

Cash flow in USDView more

In 2024, Regenxbio Inc increased its cash reserves by 62.93%, or 23.00m. Cash Flow from Investing totalled 103.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 173.13m for operations while cash generated from financing totalled 92.68m.
Cash flow per share-3.16
Price/Cash flow per share--
Book value per share3.19
Tangible book value per share3.19
More ▼

Balance sheet in USDView more

Regenxbio Inc has a Debt to Total Capital ratio of 54.27%, a higher figure than the previous year's 11.63%.
Current ratio2.66
Quick ratio--
Total debt/total equity1.19
Total debt/total capital0.5427
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.